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LETTERS TO THE EDITORAn Unmet Need in the WHO
2015 Biopsy Classiﬁcation:
Poorly Differentiated
NSCCs with Positive
Neuroendocrine MarkersTo the Editor:
It is with great interest that we read the recent
World Health Organization (WHO) Classiﬁcation 2015
of lung tumors and the state-of-the-art concise review
by Travis et al. published in the Journal of Thoracic
Oncology.1 The diagnostic criteria for small biopsy
specimens are especially interesting and clinically
relevant.
The new classiﬁcation for biopsy specimens to di-
agnose non–small cell lung carcinoma (NSCLC) without
clear morphologic features is driven largely by immu-
nohistochemical (IHC) markers. This classiﬁcation
(Fig. 1) categorizes NSCLC as follows: (1) non–small cell
carcinoma (NSCC), favor adenocarcinoma (positive for
thyroid transcription factor 1), (2) NSCC, favor squa-
mous cell carcinoma (p63/p40þ), or (3) NSCC, not
otherwise speciﬁed (no morphologic features and
negative for IHC markers). Moreover, when neuroen-
docrine (NE) morphologic features are present, testing
for NE markers should be performed, and when the
results are positive, the diagnosis “NSCC, favor large cell
NE carcinoma (LCNEC)” is preferred. Finally, the diag-
nostic term for NSCC with morphologic features of NE
in the absence of NE IHC markers is NSCC when
LCNEC is suspected but stains fail to demonstrate NE
differentiation. Following this classiﬁcation, one cate-
gory is missing, namely, NSCC without distinct (NE)
morphologic features but with positive NE IHC markers,
which in this letter is referred as NSCC NE IHCþ (see
Fig. 1).
The value of the diagnosis NSCC NE IHCþ has been
heavily debated. As many as 10% to 30% of surgically
resected NSCLCs have NE differentiation in IHC
staining, but no clear association with prognosis hasAddress for correspondence: Anne-Marie C. Dingemans, MD, PhD,
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NSCLC with morphologic features of squamous cell
carcinoma or adenocarcinoma, however, and often
only a single NE IHC marker was positive. Moreover,
these studies did not report on poorly differentiated
NSCC NE IHCþ in the absence of thyroid
transcription factor 1 or P63 staining. Therefore, the
value of an NSCC NE IHCþ classiﬁcation on the basis
of biopsy specimens is rather unclear and requires
further investigation.
Because an NE growth pattern in biopsy specimens
is difﬁcult to recognize, the diagnosis LCNEC may be
missed and the incorrect diagnosis of NSCC not other-
wise speciﬁed made. This misdiagnosis is problematic
because the prognosis of LCNEC has been shown to be
worse than that of squamous cell carcinomas and ad-
enocarcinomas.4 Moreover, we have observed that since
2007, the diagnosis of LCNEC on the basis of biopsies
has increased dramatically in the Netherlands and
that in approximately 54% of cases, the diagnosis was
based on positive NE IHC markers and the pathology
reports did not mention morphologic features of NE
carcinoma.5 These results indicate that although not
advised by the current WHO classiﬁcation, NE IHC
markers have been commonly used in daily practice
with undifferentiated carcinomas (NSCCs) in biopsy
specimens.
In conclusion, we think that the diagnosis poorly
differentiated NSCC NE IHCþ on the basis of biopsy
specimens could be of clinical importance and is an
unmet need in the current WHO classiﬁcation. Future
studies should provide more insight into this diagnosis
on the basis of biopsy specimens.
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Figure 1. An overview of the WHO classiﬁcation of non–small cell lung carcinomas on biopsy specimens is given. On the right
side, the group of NSCCs with positive NE IHC markers, which is not addressed in the 2015 WHO classiﬁcation, is presented.
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Immunohistochemical
Markers Should Not Be
Performed in Poorly
Differentiated NSCCs in the
Absence of Neuroendocrine
Morphologic Features
according to the 2015 WHO
ClassiﬁcationIn Response:
In contrast to the recommendations of the 2015 World
Health Organization (WHO) classiﬁcation of tumors,1Derks et al. suggest that testing for neuroendocrine
(NE) immunohistochemical markers should be
performed on all poorly differentiated non–small cell
carcinomas (NSCCs) lacking NE morphologic features
and reported.2 We considered this suggestion in our
preparation of the WHO classiﬁcation, and the topic
was discussed in detail. For the 2011 International
Association for the Study of Lung Cancer/American
Thoracic Society/European Respiratory Society lung
adenocarcinoma classiﬁcation, we conducted an
evidence-based review that addressed this topic specif-
ically.3 Because there are no consistent evidence-based
data in the literature to support any clinical relevance
(diagnostic, prognostic, or therapeutic) of a positive NE
marker in the absence of NE morphologic features, the
2015 WHO Classiﬁcation recommends that testing for
NE markers not be performed on all poorly differenti-
ated NSCCs in the absence of NE morphologic features.1
This recommendation is speciﬁcally presented on
page 20 of the WHO blue book,1 and this detail could
not be included in the short review provided for
the Journal of Thoracic Oncology.4 Only if there is a
suggestion of NE morphologic features is testing for
NE immunohistochemical markers appropriate. In
addition, the problem of NSCC with NE differentiation
